We’re living in a period of extraordinary changes. High-speed communication has spread across the globe like wildfire, altering the way we collect our information, work and even play. Many folks believe rising temperatures are threatening our way of life, inspiring investors to “think green.” Donald Trump’s trillion-dollar infrastructure plans will bring billions of dollars into…
DetailsIt’s tough to argue against explosive growth. Look at online dating for example. No longer is dating online considered the last ditch effort for frustrated, introverted singles. Now, millions of people are using such services to find their matches. In fact, right now, there are 40 million Americans using online dating site and apps. More…
DetailsTo hike, or not to hike? It’s the question on every investor’s mind these days. When the Federal Reserve meets this week, odds are as high as 88.6%, per the CME Group that we could see a rate hike enacted at this meeting. There are a few reasons why we aren’t as concerned about a…
DetailsAfter a poor outing in 2016, biotech and pharmaceutical names are showing signs of life. Since December 30, the iShares NASDAQ Biotech ETF (IBB) ran from 265 to a high of 303 (+14%) and the SPDR S&P Biotech ETF (XBI) shot from 59 to a high of 72 or +22%. And while both indexes have…
DetailsThis is the market on irrational exuberance. Stocks are clearly in a bubble. And like all bubbles, this one could soon burst. At the moment, the U.S. economy has been rallying on cheap money, massive amounts of debt, and irrational exuberance. Unfortunately, history has proven that it doesn’t last. In 1929, 2000, and 2008, markets…
DetailsIt could cost up to $3.6 trillion. At least, that’s what the American Society of Civil Engineers (ASCE) says will be needed by 2020 to bring roads, bridges, dams, ports and other essential areas up to safety standards. What’s worse, that same group just gave current U.S. infrastructure a D+ rating. We’re in desperate need…
DetailsThe win streak was down for the count on Tuesday. According to the pundits, all seemed grim. CNN noted, “Dow’s ridiculous string of records finally comes to an end.” The Hill posted, “Wall Street sees Trump rally coming to an end.” But as history has proven, it wasn’t wise to count the rally as done…
DetailsWithout a doubt, it’s one of the most controversial topics on the market today. But controversial or not, some marijuana stocks have already doubled, if not tripled in the last year. GW Pharmaceuticals (GWPH) soared from $90 to $120 Kush Bottles (KSHB) jumped from $1.25 to $5 OrganiGram Holdings (OGRMF) rocketed from 80 cents to…
DetailsInvestors are waking up. The opportunity is far too great to ignore. After a dismal outing in 2016, the biotech and pharmaceutical sector is back in a big way with 80 million baby boomers, millions of newly insured Americans, and new innovation leading the charge. It’s already forced the iShares NASDAQ Biotech ETF (IBB) and…
DetailsIf you haven’t heard of Augmented Reality (AR) yet, you will… and fast. Recently Apple (NASDAQ:AAPL) CEO, Tim Cook, told folks just how huge AR could be. “I regard it as a big idea like the smartphone,” he says. “The smartphone is for everyone. We don’t have to think the iPhone is about a certain…
DetailsAfter a market-crushing year, small cap stocks are taking center stage yet again. In fact, the Russell 2000 just notched its first all-time high since December, rallying to a high of 1,396.34. And I can personally assure you the run is far from over. All thanks to growing optimism that Donald Trump will propose a…
DetailsWe all dream of uncovering that next hot buyout target. Once a deal hits the news, stocks can soar overnight. So it’s no surprise then, that many investors spend considerable effort tracking them down, as do we. In 2015, we saw $4.3 trillion in deals, smashing a $4.29 trillion record set in 2007. Pfizer announced…
Details